Asia Pacific Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infecti

Asia Pacific Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

The Asia Pacific carbapenem-based antibiotics market is expected to reach US$ 1,506.07 million by 2028 from US$ 1,072.76 million in 2021; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028.

The market's growth is attributed to factors such as the rising prevalence of bacterial infections and increasing private and public partnerships of leading pharmaceutical players. However, the tedious and expensive process of developing antibiotics is expected to restrain the market's growth during the forecast period.

Generic versions are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The main focus of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market. The increased production of generic carbapenem-based antibiotics has increased drug availability in various low- and middle-income countries.

Generic versions of carbapenem drugs available in the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). In addition, the growing number of generic players in the market is accelerating the production of generic drugs. Many Asian companies are engaged in developing active pharmaceutical ingredients (API), which are required to produce generic carbapenem-based antibiotics. In June 2021, JW Pharmaceutical, a South Korean company, announced it had completed production of its API for Ertapenem injection and shipped it to the US. The company plans to enter the global carbapenem antibiotic market in the coming years. It has also succeeded in developing its technology independently in Korea to produce Doripenem. Furthermore, the company plans to expand the sales of both API and finished drugs of Imipenem and Meropenem by exporting them to over 40 countries, including China and Japan. Therefore, accelerated generic drug production by the companies is driving the global carbapenem-based antibiotics market.

Asia Pacific Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)

ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION

By Type

Meropenem Imipenem Doripenem Tebipenem Others By Indication

Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections Others By Distribution Channel

Hospital Pharmacies Retail Pharmacies Online Pharmacies By Country

China India Japan South Korea Australia Rest of Asia Pacific Company Profiles

ACS Dobfar S.p.A Aurobindo Pharma Ltd DAEWOONG PHARMACEUTICAL CO., LTD Gland Pharma Limited Merck & Co., Inc. Sumitomo Dainippon Pharma Co., Ltd. Savior Lifetec Pfizer Inc. Spero Therapeutic

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Paciifc carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Paciifc carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.